Highlights Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

End-of-day quote Nyse Other stock markets 23:00:00 04/02/2024 GMT			5-day change	1st Jan Change
2.02 ^USD	-3.35%		-4.04%	-8.18%

06-10	Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	CI
06-06	Transcript : Can-Fite BioPharma Ltd. - Special Call

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	06-10	CI
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	06-05	CI
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	05-09	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	05-06	CI
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	04-03	CI
Can-Fite Biopharma Ltd. Announces Clinical Update	03-28	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Can-Fite Biopharma Ltd. to Present Data from the Pancreatic and Liver Cancer Programs	03-11	CI
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the Canadian Intellectual Property Office	02-28	CI
Can-Fite BioPharma Ltd. Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication	01-30	CI
Can-Fite Biopharma Ltd. Announces Results from Randomized Phase 3 Clinical Trial	01-29	CI
Can-Fite BioPharma Ltd. Reports New Data on Namodenoson?s Anti-Obesity Mechanism of Action	12-20	CI
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan	12-18	RE
Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson	12-18	CI
Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients	12-04	CI
Can-Fite BioPharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-30	CI
Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson	11-21	CI
Can-Fite Biopharma Ltd. Provides Business Update	11-01	CI
Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal	30/10/23	CI
Can-Fite Biopharma Ltd. Enters into an Agreement with Collaborations Pharmaceuticals Inc to Develop Anti-Cancer Drugs Utilizing Artificial Intelligence	26/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

Highlights

Filters